Why Is My Anti-Mullerian Hormone Normal but I Still Feel Awful?

Why Is My Anti-Mullerian Hormone Normal but I Still Feel Awful?

Yes, this is very common. AMH (anti-Müllerian hormone) tells your doctor how many eggs you have left — it is a measure of ovarian reserve, not a measure of how well your hormones are functioning day-to-day. A normal AMH result rules out premature ovarian insufficiency, but it says almost nothing about estrogen, progesterone, cortisol, thyroid, or the dozens of other signals that determine how you actually feel. If your AMH is normal and you still feel terrible, the answer is almost certainly somewhere else in your biology.

---

What AMH Actually Measures — and What It Doesn't

Anti-Müllerian hormone is secreted by the granulosa cells of small antral and pre-antral follicles in the ovaries. Its serum level rises and falls with the size of that follicle pool, which is why fertility specialists use it to predict ovarian response to stimulation and estimate reproductive lifespan (Dewailly et al., Human Reproduction Update 2014; PMID: 24516083).

That is genuinely useful information — but the test was designed for reproductive medicine, not general wellbeing. Here is what AMH does not measure:

• Estradiol (E2) levels or estrogen/progesterone balance
• Luteinizing hormone (LH) or follicle-stimulating hormone (FSH) dynamics
• Thyroid function (TSH, Free T4, Free T3)
• Adrenal output or cortisol rhythm
• Insulin sensitivity or blood sugar regulation
• Inflammation or iron status
• Neurotransmitter tone or sleep architecture

A normal AMH in someone with subclinical hypothyroidism, low progesterone, elevated cortisol, or poor sleep is still going to feel awful — because none of those problems show up on an AMH test. If this pattern resonates with you, the experience of having normal labs that still leave you feeling terrible is more common than most clinicians acknowledge.

It is also worth understanding the numerical context. The clinical "normal" range for AMH varies by laboratory, but most use something like 1.0–3.5 ng/mL for reproductive-age women. Being at 1.1 ng/mL (technically normal but low-normal) and being at 3.4 ng/mL are very different biological situations for fertility, yet both people might walk out with the same reassuring phrase: "your AMH is normal." Neither number, however, tells the clinician anything about progesterone luteal phase length, estrogen receptor sensitivity, or adrenal androgen balance.

---

Why Intense Cravings, Mood Swings, and Emotional Volatility Can Coexist With Normal AMH

One of the most frequently reported symptoms from people who have normal AMH results is an experience that can feel almost physical in its urgency: cravings that arrive like a wave, emotional volatility that seems disproportionate to the trigger, and a sense of being wired and depleted at the same time. These symptoms are not random. They have a mechanistic explanation rooted in how sex hormones interact with the brain's reward and impulse-control circuitry — circuitry that AMH has no window into.

Estradiol and progesterone both modulate dopaminergic and serotonergic tone in the prefrontal cortex and limbic system. When progesterone is low in the luteal phase, or when estradiol fluctuates sharply (as it commonly does in perimenopause or in cycles disrupted by stress), the brain's inhibitory control weakens. The result is exactly the kind of craving intensity and emotional volatility people describe — a feeling of being about to "implode" if a specific sensory need isn't met. This is not a willpower failure; it is a neurochemical state.

Research on premenstrual dysphoric disorder (PMDD) illustrates this clearly. Bäckström et al. found that women with PMDD show heightened sensitivity to the neurosteroid allopregnanolone (a progesterone metabolite) in GABA-A receptors during the luteal phase, producing paradoxical excitation rather than sedation (Trends in Neurosciences 2014; PMID: 24529619). The same progesterone fluctuation that a standard panel might classify as "within range" is enough to flip GABA receptor behavior in susceptible individuals.

AMH doesn't measure any of this. A woman with PMDD-level neurosteroid sensitivity can have a perfectly normal AMH of 2.5 ng/mL and still experience monthly cycles of craving, rage, or despair that make daily functioning genuinely difficult.

If you also have ADHD, the picture compounds further. Dopamine dysregulation in ADHD interacts with estrogen signaling — estrogen upregulates dopamine transporter expression and affects striatal dopamine availability. A luteal-phase estrogen drop in someone with already-borderline dopamine function can push them well below their functional threshold, producing cravings and impulsivity that feel extreme even to them. This is a real, documented neurobiological phenomenon, not an overreaction.

---

The Thyroid–Hormone Cycle Trap: Why Adjusting One Variable Breaks Another

A second pattern that appears frequently alongside a "normal AMH" result is the exhausting thyroid medication loop: you feel hypothyroid, your dose goes up, you lose weight and feel better briefly, then you go hyperthyroid, your dose comes down, and the cycle repeats with no stable landing point.

This cycle is rarely about the thyroid medication itself. It is almost always about the interaction between thyroid hormone, sex hormone-binding globulin (SHBG), and estrogen. Here is the chain of events:

1. Hypothyroid state: Low T3/T4 reduces basal metabolic rate, promotes weight gain, and raises SHBG (paradoxically).
2. Levothyroxine dose increase: Thyroid status improves, but rising T4/T3 also alters estrogen metabolism via hepatic enzymes — specifically, thyroid hormones influence cytochrome P450 enzymes that clear estrogens.
3. Estrogen shifts: The change in estrogen balance affects SHBG again, which in turn changes how much free testosterone and estradiol are bioavailable.
4. Cortisol responds: Adrenal output adjusts to the new metabolic rate, sometimes producing temporary hyperthyroid-like symptoms (heart racing, anxiety, insomnia) even when TSH is technically in range.

The result is a person who oscillates between feeling awful in opposite directions, with labs that may look acceptable at each extreme. AMH is nowhere in this picture. Understanding your SHBG levels in relation to how you feel can be a critical piece of decoding this loop, as can looking carefully at free T4 trends over time rather than single-point snapshots.

A 2021 analysis published in Thyroid confirmed that levothyroxine-treated women have significantly more residual symptoms than men at identical TSH values, and that estrogen status is a key moderating variable (Idrees et al., Thyroid 2021; PMID: 33356920). This is not a subjective complaint — it is a documented pharmacokinetic reality that standard thyroid dosing protocols do not yet account for systematically.

---

Why Sleep Anxiety and Nighttime Dread Are Hormonal, Not Just Psychological

Another symptom cluster that sits entirely outside AMH's scope is nighttime anxiety — the kind that makes going to sleep feel genuinely frightening rather than restful. This is not simply "general anxiety." For many hormonally dysregulated individuals, it has a specific physiological driver: the cortisol nadir.

Cortisol follows a diurnal rhythm, peaking within 30–45 minutes of waking (the cortisol awakening response, or CAR) and reaching its lowest point around midnight. In people with dysregulated HPA (hypothalamic-pituitary-adrenal) axis function — which is common in anyone under chronic stress, recovering from illness, or experiencing perimenopausal hormonal shifts — this nadir can be accompanied by a brief surge of adrenaline (epinephrine) that the body produces to prevent blood glucose from dropping too low during sleep.

That adrenaline surge is experienced consciously as dread, heart racing, a sense that something is wrong. The brain, searching for an explanation, latches onto whatever is emotionally salient — in this case, fears about sleep itself, which then become reinforced as a conditioned response. Over time, the bed becomes a cue for anxiety rather than rest.

Estrogen and progesterone both directly modulate the HPA axis. Progesterone's metabolite allopregnanolone is itself a potent positive allosteric modulator of GABA-A receptors — meaning it is one of the brain's natural anxiolytics. When progesterone drops (in the luteal phase, in perimenopause, or under chronic stress), this endogenous calming effect weakens, and nighttime adrenaline surges become more likely (Genazzani et al., Gynecological Endocrinology 2007; PMID: 17454166).

None of this is visible on an AMH test. A woman with excellent ovarian reserve (AMH of 3.0 ng/mL) and severely disrupted progesterone production can be lying awake every night in genuine physiological distress, dismissed because her "hormones look fine."

If this resonates with you, your cortisol pattern across the day is a far more relevant test than AMH when sleep anxiety is the primary complaint. A 4-point salivary cortisol test ordered by a functional medicine physician or endocrinologist can map the actual rhythm rather than a single snapshot.

---

The Broader Pattern: Normal Labs, Real Symptoms

AMH is one of a larger category of lab values that can be technically normal while leaving a significant gap between the result and how you actually feel. The pattern is consistent across many markers:

This is not a criticism of lab testing — it is a reminder that any single marker is a narrow window. If you have been told your B12 is normal but still feel exhausted or find yourself wondering why normal homocysteine hasn't resolved your cognitive fog, the issue is almost always the gap between a reference-range snapshot and the full functional picture.

---

What Tests Actually Tell You Why You Feel This Way

If your AMH is normal and you still feel terrible, the following additional assessments are the most likely to reveal the actual driver:

Hormonal panel (timed to cycle):

• Estradiol (E2) and progesterone on day 21–22 of a 28-day cycle (mid-luteal)
• LH and FSH on days 2–4 (early follicular)
• DHEA-S and total/free testosterone
• SHBG (to calculate free hormone fractions)

Thyroid panel (comprehensive):

• TSH, Free T4, Free T3, Reverse T3
• TPO antibodies and thyroglobulin antibodies

Metabolic and inflammatory markers:

• Fasting insulin and HOMA-IR (insulin resistance)
• hsCRP (high-sensitivity C-reactive protein)
• Ferritin (not just hemoglobin — ferritin can be low even when hemoglobin is normal)
• Homocysteine and methylmalonic acid (functional B12 status)

HPA axis:

• 4-point salivary cortisol (morning, noon, afternoon, evening)
• DHEA-S as a counterregulatory adrenal marker

A 2019 consensus statement from the Endocrine Society emphasized that hormonal symptoms should be evaluated with multiple timed measurements rather than single-point serum draws, particularly in perimenopausal women whose hormone levels fluctuate dramatically within and between cycles (Santoro et al., Journal of Clinical Endocrinology & Metabolism 2020; PMID: 32520982).

---

What This Means for Your Formula

Ones is a personalized supplement platform that analyzes your blood work, wearable data, and health history to build a custom capsule formula calibrated to your actual findings — not a generic women's wellness stack.

For someone presenting with the pattern described in this article (normal AMH, disrupted mood and cravings, sleep anxiety, hormonal cycling), the most relevant ingredients — if the underlying data supports them — tend to include:

• Ashwagandha (KSM-66, 600 mg): One of the most rigorously studied adaptogens for HPA axis regulation. A randomized controlled trial by Chandrasekhar et al. found that 600 mg/day of KSM-66 over 60 days reduced serum cortisol by 27.9% and significantly reduced scores on validated stress and anxiety scales in chronically stressed adults (Indian Journal of Psychological Medicine 2012; PMID: 23439798). If your data shows a dysregulated cortisol rhythm driving nighttime anxiety, this is the mechanistically appropriate intervention.
• Magnesium Complex (including Magnesium Glycinate): Magnesium acts as a natural NMDA receptor antagonist and supports GABA receptor function. Low intracellular magnesium is associated with heightened HPA reactivity, poor sleep architecture, and increased susceptibility to anxiety. Ones includes a Magnesium Complex blend dosed to clinical ranges for individuals whose labs and wearable data suggest magnesium insufficiency.
• Adrenal Support (System Blend): Ones' proprietary Adrenal Support blend is designed for individuals whose data shows signs of adrenal fatigue or HPA dysregulation — a pattern that frequently underlies the sleep-dread cycle and hormonal oscillation described in this article.

Ones does not stock progesterone or estradiol (those require a prescription), but supporting the HPA axis and micronutrient status that modulate how those hormones are produced and cleared is within the scope of what a personalized formula can do meaningfully. The AI practitioner selects from a 6 or 9-capsule daily plan based on the depth and breadth of your findings — the formula is built around your data, not a category.

---

Key Takeaways

• AMH measures ovarian reserve only. A normal result tells you nothing about estrogen/progesterone balance, thyroid function, adrenal output, insulin sensitivity, or the neurochemical drivers of mood, cravings, and sleep.
• Intense cravings and emotional volatility with normal labs are often neurosteroid-driven. Fluctuating progesterone alters GABA-A receptor behavior in ways that are real and measurable — and completely invisible to an AMH test.
• The thyroid medication cycle is frequently a sex hormone–SHBG interaction problem, not a dosing error. Estrogen status modulates thyroid hormone metabolism at the hepatic enzyme level.
• Nighttime sleep anxiety often has a physiological driver — specifically, an adrenaline response to the cortisol nadir that is amplified when progesterone (and its GABA-modulating metabolite allopregnanolone) is low.
• A complete hormonal workup should be timed to the menstrual cycle and include free hormone fractions, not just total levels. Single-point serum draws miss the dynamic picture.
• Personalized supplementation can address the upstream drivers — HPA regulation, micronutrient status, inflammation — even when the root cause is hormonal. Matching the intervention to your data is what separates targeted support from guesswork.